NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom